Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

Endothelial activation and damage as a common pathological substrate in different pathologies and cell therapy complications

  • Palomo, Marta|||0000-0002-3261-6577
  • Moreno-Castaño, Ana Belén|||0000-0003-0338-7514
  • Salas, María Queralt|||0000-0003-4567-3682
  • Escribano Serrat, Silvia|||0000-0001-9499-8999
  • Rovira Argelagués, Montserrat|||0000-0001-7786-9079
  • Guillén-Olmos, Elena
  • Fernandez, Sara
  • Ventosa-Capell, Helena
  • Youssef, Lina|||0000-0002-0554-5507
  • Crispi, Fatima|||0000-0002-7422-5240
  • Nomdedeu, Meritxell
  • Martínez Sánchez, Julia
  • De Moner, Blanca
  • Diaz-Ricart, Maribel|||0000-0003-1122-0052
The endothelium is a biologically active interface with multiple functions, some of them common throughout the vascular tree, and others that depend on its anatomical location. Endothelial cells are continually exposed to cellular and humoral factors, and to all those elements (biological, chemical, or hemodynamic) that circulate in blood at a certain time. It can adapt to different stimuli but this capability may be lost if the stimuli are strong enough and/or persistent in time. If the endothelium loses its adaptability it may become dysfunctional, becoming a potential real danger to the host. Endothelial dysfunction is present in multiple clinical conditions, such as chronic kidney disease, obesity, major depression, pregnancy-related complications, septic syndromes, COVID-19, and thrombotic microangiopathies, among other pathologies, but also in association with cell therapies, such as hematopoietic stem cell transplantation and treatment with chimeric antigen receptor T cells. In these diverse conditions, evidence suggests that the presence and severity of endothelial dysfunction correlate with the severity of the associated disease. More importantly, endothelial dysfunction has a strong diagnostic and prognostic value for the development of critical complications that, although may differ according to the underlying disease, have a vascular background in common. Our multidisciplinary team of women has devoted many years to exploring the role of the endothelium in association with the mentioned diseases and conditions. Our research group has characterized some of the mechanisms and also proposed biomarkers of endothelial damage. A better knowledge would provide therapeutic strategies either to prevent or to treat endothelial dysfunction.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Characterization of the endotheliopathy, innate-immune activation and hemostatic imbalance underlying CAR-T cell toxicities, Laboratory tools for an early and differential diagnosis

  • Moreno-Castaño, Ana Belén|||0000-0003-0338-7514
  • Fernández, Sara
  • Ventosa-Capell, Helena
  • Palomo, Marta|||0000-0002-3261-6577
  • Martínez Sánchez, Julia
  • Ramos, Alex|||0000-0003-1333-5144
  • Ortiz-Maldonado, Valentín|||0000-0003-4699-6862
  • Delgado, Julio|||0000-0002-5157-4376
  • Fernández de Larrea, Carlos|||0000-0003-4930-9255
  • Urbano Ispizua, Álvaro|||0000-0002-7529-9399
  • Penack, Olaf|||0000-0003-4876-802X
  • Nicolás, J.M.
  • Téllez, Adrian
  • Escolar, Ginès
  • Carreras, Enric|||0000-0002-3134-9964
  • Fernandez Aviles, Francesc|||0000-0003-3051-3926
  • Castro Rebollo, Pedro|||0000-0002-6118-8970
  • Diaz-Ricart, Maribel|||0000-0003-1122-0052
Background Chimeric antigen receptor (CAR)-T cell-based immunotherapy constitutes a revolutionary advance for treatment of relapsed/refractory hematological malignancies. Nevertheless, cytokine release and immune effector cell-associated neurotoxicity syndromes are life-threatening toxicities in which the endothelium could be a pathophysiological substrate. Furthermore, differential diagnosis from sepsis, highly incident in these patients, is challenging. Suitable laboratory tools could be determinant for their appropriate management. Methods Sixty-two patients treated with CAR-T cell immunotherapy for hematological malignancies (n=46 with CD19-positive diseases, n=16 with multiple myeloma) were included. Plasma samples were obtained: before CAR-T cell infusion (baseline); after 24-48 hours; at suspicion of any toxicity onset and 24-48 hours after immunomodulatory treatment. Biomarkers of endothelial dysfunction (soluble vascular cell adhesion molecule 1 (sVCAM-1), soluble TNF receptor 1 (sTNFRI), thrombomodulin (TM), soluble suppression of tumorigenesis-2 factor (ST2), angiopoietin-2 (Ang-2)), innate immunity activation (neutrophil extracellular traps (NETs), soluble C5b-9 (sC5b-9)) and hemostasis/fibrinolysis (von Willebrand Factor antigen (VWF:Ag), ADAMTS-13 (A13), α2-antiplasmin (α2-AP), plasminogen activator inhibitor-1 antigen (PAI-1 Ag)) were measured and compared with those in cohorts of patients with sepsis and healthy donors. Results Patients who developed CAR-T cell toxicities presented increased levels of sVCAM-1, sTNFRI and ST2 at the clinical onset versus postinfusion values. Twenty-four hours after infusion, ST2 levels were good predictors of any CAR-T cell toxicity, and combination of ST2, Ang-2 and NETs differentiated patients requiring intensive care unit admission from those with milder clinical presentations. Association of Ang-2, NETs, sC5b-9, VWF:Ag and PAI-1 Ag showed excellent discrimination between severe CAR-T cell toxicities and sepsis. Conclusions This study provides relevant contributions to the current knowledge of the CAR-T cell toxicities pathophysiology. Markers of endotheliopathy, innate immunity activation and hemostatic imbalance appear as potential laboratory tools for their prediction, severity and differential diagnosis.